# Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment

> **NCT01158079** · PHASE1 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 7 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** ALN-VSP02

## Key facts

- **NCT ID:** NCT01158079
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2012-08
- **Final completion:** 2012-09
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2012-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01158079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01158079, "Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01158079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*